Adalimumab biosimilar (CinnaGen)

阿达木单抗生物类似药 (CinnaGen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (CinnaGen)

Drug Alias Name阿达木单抗生物仿制药 (CinnaGen)Adalimumab (CinnaGen)Adalimumabum (CinnaGen)阿达莫单抗生物仿制药 (CinnaGen)阿达利木单抗生物仿制药 (CinnaGen) +[6]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesCinnagen

China Registration ClassN/A

Active CompaniesCinnagen

Inactive CompaniesN/A

Active IndicationsArthritis, Rheumatoid

Inactive IndicationsN/A

ATC CodeL04AB04